Search research articles
Contact Us
Filters
Showing results (191-200 of 386) with videos related to
Page
of 39
Sort By:
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Journal of Hepatology
|
December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study
Lise Retat, Laura Webber, Peter Jepsen, et al.
Viruses
|
July 29, 2023
Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in Spain
Adriana Palom, Edurne Almandoz, Antonio Madejón, et al.
Infection and Drug Resistance
|
December 7, 2018
Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant
Celia Perales, Qian Chen, Maria Eugenia Soria, et al.
The Journal of General Virology
|
December 15, 2017
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors
Laura Ordeig, Damir Garcia-Cehic, Josep Gregori, et al.
Journal of Hepatology
|
July 15, 2024
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
Maria Buti, Heiner Wedemeyer, Soo Aleman, et al.
Journal of Hepatology
|
April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
Xavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Maria Buti, Stuart C Gordon, Eli Zuckerman, et al.
World Journal of Gastroenterology
|
May 23, 2018
Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy
Carolina González, David Tabernero, Maria Francesca Cortese, et al.
The Lancet Regional Health. Europe
|
September 22, 2025
Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
Devin M Razavi-Shearer, Loreta A Kondili, Samantha Hall, et al.
Page
of 39
Search research articles
Search
Showing results (191-200 of 386) with videos related to
Sort By:
Page
of 39
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, et al.
Journal of Hepatology
|
December 13, 2023
Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study
Lise Retat, Laura Webber, Peter Jepsen, et al.
Viruses
|
July 29, 2023
Community Strategy for Hepatitis B, C, and D Screening and Linkage to Care in Mongolians Living in Spain
Adriana Palom, Edurne Almandoz, Antonio Madejón, et al.
Infection and Drug Resistance
|
December 7, 2018
Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant
Celia Perales, Qian Chen, Maria Eugenia Soria, et al.
The Journal of General Virology
|
December 15, 2017
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors
Laura Ordeig, Damir Garcia-Cehic, Josep Gregori, et al.
Journal of Hepatology
|
July 15, 2024
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
Maria Buti, Heiner Wedemeyer, Soo Aleman, et al.
Journal of Hepatology
|
April 22, 2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
Xavier Forns, Stuart C Gordon, Eli Zuckerman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 16, 2015
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE
Maria Buti, Stuart C Gordon, Eli Zuckerman, et al.
World Journal of Gastroenterology
|
May 23, 2018
Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy
Carolina González, David Tabernero, Maria Francesca Cortese, et al.
The Lancet Regional Health. Europe
|
September 22, 2025
Estimating the impact of displacement from Ukraine on HBV and HCV prevalence among migrants in the European Union, 2024: a modeling study
Devin M Razavi-Shearer, Loreta A Kondili, Samantha Hall, et al.
Page
of 39